Serum M2BPGi as a predictor of hepatocellular carcinoma development in chronic hepatitis B and C: a systematic review and meta-analysis - Takeaways - MDSpire

Serum M2BPGi as a predictor of hepatocellular carcinoma development in chronic hepatitis B and C: a systematic review and meta-analysis

  • By

  • Yunchul Park

  • Younggoun Jo

  • Hyo-Sin Kim

  • Sola Lee

  • Hong-Sung Jung

  • Ho-Kyun Lee

  • Soo Jin Na Choi

  • July 15, 2026

Share

  • 1

    Hepatocellular carcinoma (HCC) is responsible for approximately 830,000 deaths annually, primarily arising from chronic viral hepatitis.

  • 2

    Mac-2 binding protein glycosylation isomer (M2BPGi) is a serum biomarker associated with liver fibrosis and elevated levels are linked to HCC.

  • 3

    A meta-analysis of 23 studies found a pooled hazard ratio of 4.61 for HCC development in patients with elevated M2BPGi.

  • 4

    The association between elevated M2BPGi and HCC holds across different viral etiologies and treatment statuses.

  • 5

    Funnel asymmetry suggests the true risk increase associated with elevated M2BPGi may be closer to 3.5-fold rather than 4.6-fold.

Original Source(s)

Serum M2BPGi as a predictor of hepatocellular carcinoma development in chronic hepatitis B and C: a systematic review and meta-analysis

  • by Yunchul Park, Younggoun Jo, Hyo-Sin Kim, Sola Lee, Hong-Sung Jung, Ho-Kyun Lee, Soo Jin Na Choi

  • July 15, 2026

Related Content

Mechanistic insights into ferroptosis and its therapeutic potential in hepatocellular carcinoma

Helicobacter pylori infection in gastric cancer patients in French Guiana: a hospital-based study (2018–2023)

Efficacy and safety of bupleurum-containing formulas combined with chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis